In 2024, global funding for healthcare and AI startups surpassed $7.5 billion, although it still fell short of the levels seen in 2021.

The largest funding round of the year was a remarkable $1 billion secured by Xaira Therapeutics, an AI drug discovery platform, with backing from Arch Venture Partners and Foresite Capital.

Formation Bio successfully raised $372 million in a Series D funding round, aimed at advancing its AI-driven drug development process.

Hippocratic AI raised $141 million in Series B funding, achieving a valuation of $1.64 billion, while Insilico Medicine garnered $100 million in Series E funding for its AI applications in pharmaceutical research and development.

Innovaccer kicked off 2025 by raising $275 million for its AI-enabled cloud tracking platform designed for healthcare providers.

Abridge also made headlines by obtaining $250 million in Series D funding for its AI-driven clinician conversation platform.

As of early 2025, nearly $1.68 billion has already been invested in AI-enabled health startups, signaling a robust start to the year.

Despite a broader slowdown in tech IPOs, the outlook for public offerings in the biotech sector remains positive.

Tempus AI went public in June 2024, enjoying a strong stock performance and achieving a market cap of around $11 billion, while Metagenomi and Alto Neuroscience have faced significant challenges post-IPO, with Metagenomi's shares plummeting over 70%.

Investors continue to show enthusiasm for funding AI and healthcare startups, with expectations for further increases as more companies adopt AI technologies.